$30,000 of ACADIA PHARMACEUTICALS lobbying was just disclosed, from Q4 of 2025, in a new Lobbying Disclosure Act filing.
This included lobbying on issues like:
"General Medicare and Medicaid Issues. Prescription drug payment reform. Pharmaceutical supply chain."
You can find more data on corporate lobbying on Quiver Quantitative.
ACAD Insider Trading Activity
ACAD insiders have traded $ACAD stock on the open market 6 times in the past 6 months. Of those trades, 0 have been purchases and 6 have been sales.
Here’s a breakdown of recent trading of $ACAD stock by insiders over the last 6 months:
- MARK C. SCHNEYER (EVP, CHIEF FINANCIAL OFFICER) has made 0 purchases and 3 sales selling 35,760 shares for an estimated $879,865.
- JAMES M DALY sold 30,000 shares for an estimated $670,983
- JAMES KIHARA (PRINCIPAL ACCOUNTING OFFICER) sold 4,084 shares for an estimated $96,753
- ELIZABETH A. GAROFALO sold 1,600 shares for an estimated $41,560
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
ACAD Hedge Fund Activity
We have seen 181 institutional investors add shares of ACAD stock to their portfolio, and 139 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- MORGAN STANLEY removed 2,922,841 shares (-71.1%) from their portfolio in Q3 2025, for an estimated $62,373,426
- CITADEL ADVISORS LLC removed 2,689,176 shares (-89.3%) from their portfolio in Q3 2025, for an estimated $57,387,015
- BRAIDWELL LP added 2,378,655 shares (+inf%) to their portfolio in Q3 2025, for an estimated $50,760,497
- ADAGE CAPITAL PARTNERS GP, L.L.C. added 1,880,356 shares (+311.4%) to their portfolio in Q3 2025, for an estimated $40,126,797
- POINT72 ASSET MANAGEMENT, L.P. removed 1,686,154 shares (-53.1%) from their portfolio in Q3 2025, for an estimated $35,982,526
- MILLENNIUM MANAGEMENT LLC added 1,414,315 shares (+2052.1%) to their portfolio in Q3 2025, for an estimated $30,181,482
- ARROWSTREET CAPITAL, LIMITED PARTNERSHIP added 1,312,426 shares (+390.1%) to their portfolio in Q3 2025, for an estimated $28,007,170
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
ACAD Analyst Ratings
Wall Street analysts have issued reports on $ACAD in the last several months. We have seen 7 firms issue buy ratings on the stock, and 1 firms issue sell ratings.
Here are some recent analyst ratings:
- Citigroup issued a "Buy" rating on 01/06/2026
- UBS issued a "Buy" rating on 01/06/2026
- JP Morgan issued a "Overweight" rating on 11/17/2025
- Needham issued a "Buy" rating on 11/06/2025
- TD Cowen issued a "Buy" rating on 09/11/2025
- JMP Securities issued a "Market Outperform" rating on 08/07/2025
- RBC Capital issued a "Outperform" rating on 08/07/2025
To track analyst ratings and price targets for ACAD, check out Quiver Quantitative's $ACAD forecast page.
ACAD Price Targets
Multiple analysts have issued price targets for $ACAD recently. We have seen 11 analysts offer price targets for $ACAD in the last 6 months, with a median target of $32.0.
Here are some recent targets:
- Ashwani Verma from UBS set a target price of $40.0 on 01/06/2026
- Yigal Nochomovitz from Citigroup set a target price of $36.0 on 01/06/2026
- Ananda Ghosh from HC Wainwright & Co. set a target price of $37.0 on 12/15/2025
- Paul Matteis from Stifel set a target price of $25.0 on 12/11/2025
- Uy Ear from Mizuho set a target price of $29.0 on 12/02/2025
- Tessa Romero from JP Morgan set a target price of $31.0 on 11/17/2025
- Ami Fadia from Needham set a target price of $29.0 on 11/06/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information.
